General topics

Title Study Year Journal/Event
A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).

Sehouli J, Tomè O, Dimitrova D, Camara O, Runnebaum IB, Tessen HW, et al. J Cancer Res Clin Oncol. 2016.

TREOSULFAN 2016 J Cancer Res Clin Oncol.
Overall survival of 4865 patients with metastatic solid tumours treated in German routine practice – combined results from four prospective, multicentre cohort studies.

Marschner N, Potthoff K, Schnell R, Tesch H, Zahn M-O, Hegewisch-Becker S, et al. Oncol Res Treat. 2016;39 (suppl.3)(V174):43.

over all registries 2016 DGHO
Impact of age on the safety and efficacy of bevacizumab (BEV)-containing therapy in patients (pts) with primary ovarian cancer (OC): Analyses from the OTILIA German non-interventional study on behalf of the North-Eastern German Society of Gynaecological Oncology (NOGGO) Ovarian Cancer Working Group.

Mustea M, Mahner S, Wimberger P, Oskay-Özcelik G, Jungberg P, Meinerz W, et al. 2016;(ESMO).

OTILIA 2016 ESMO
Patient-reported outcomes in elderly bevazizumab-treated primary ovarian cancer patients: OTILIA study on behalf of the north-eastern german society of gynaecological oncology.

Sehouli J, Wimberger P, Oskay-Oezcelik G, Jungberg P, Meinerz W, Janssen J, et al. 2016;(IGCS-0471).

OTILIA 2016 IGCS
Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry.

Steinmetz T, Schröder J, Plath M, Link H, Vogt M, Frank M, Marschner N. Anemia. 2016 Feb 4;2016:e8057650.

TAR 2016 Anemia
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim – First Interim Analysis.

Kurbacher CM, Fietz T, Diel IJ, Egert M, Hurtz H-J, Lück A, et al. Oncol Res Treat. 2015;38(5):221-9.

NADIR 2015 Oncol ResTreat
Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevazizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany.

Mustea A, Oskay-Oezcelik G, Wimberger P, Reichert D, Forstbauer H, Keller M, et al. 2015;2754.

OTILIA 2015 ECCO (ESMO)
Chemotherapy-induced nausea and vomiting – treatment and patient-reported outcomes in German outpatient cancer centres: final data from the EMESIS-Registry.

Schröder J, Wiegand J, Dörfel S, Lerchenmüller C, Jänich S, Boller E, et al. Supportive Care in Cancer – Abstracts of the 2015 International MASCC/ISOO Symposium. 2015 Jun;23(suppl 1):139.

Emesis-Register 2015 MASCC
Anti-anemic treatment of cancer patients in German routine practice – data from a prospective cohort study, the Tumor Anemia Registry (TAR).

Steinmetz T, Schröder J, Plath M, Link H, Vogt M, Frank M, et al. Supportive Care in Cancer – Abstracts of the 2015 International MASCC/ISOO Symposium. 2015 Jun;23(suppl 1):361.

TAR 2015 MASCC
Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.

Tesch H, Ulshöfer T, Vehling-Kaiser U, Ottillinger B, Bulenda D, Turner M. Oncol Res Treat. 2015;38(4):146-52.

Filgrastim-NIS 2015 Oncol Res Treat
Antianämische Therapien bei Patientinnen mit Mammakarzinom: Daten aus dem Tumoranämie-Register.

Steinmetz T, Schlag R, Sandner R, Semsek D, Frank M, Vogt M, et al. Senologie – Zeitschrift für Mammadiagnostik und -therapie. 2014;(11):A133.

TAR 2014 DGHO
Wirksamkeit der Tumoranämiebehandlung im klinischen Alltag: Daten aus dem Tumoranämie-Register

Steinmetz, T., Köhler, A., Groschek, M., Koenigsmann, M., Vogt, M., Frank, M., Jänicke, M., Marschner, N. OncolResTreat 2014; 37(suppl.5)(P534)

TAR 2014 DGHO
Treatment of chemotherapy-induced neutropenia with Lipegfilgrastim (Lonquex®): First interim analysis of the non-interventional study NADIR.

Kurbacher C, Diel I, Egert M, Fietz T, Hurtz H, Lück A, et al. Oncol Res Treat. 2014;37(suppl 5)(P512).

NADIR-NIS 2014 DGHO
Routine treatment of anemia in cancer patients in Germany – data from the clinical registry on anemia-therapy (TAR Registry).

Steinmetz T, Wierecky J, Rauh J, Selak E, Vogt M, Hartmann H, u. a. Onkologie. 2013;(V712).

TAR 2013 DGHO
Bone metastasis in solid tumors in German outpatient centers – data from clinical registries.

Hartmann H, Fietz T, Köhler A, Marschner N. Onkologie. 2013;(P842).

Tumorregister 2013 DGHO
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, u. a. Ann Oncol. 2013;24(2):475–82.

Ferinject-NIS 2013 Ann Oncol
Routine treatment of anemia in cancer patients in Germany – data from the clinical registry on anemia-therapy (TAR Registry).

Steinmetz T, Reichert D, Zimber J, Hartmann H, Vogt M, Marschner N. Onkologie. 2012;35 (Suppl.6)(V838):250.

TAR 2012 DGHO
Noninterventional study HEXAFIL: analysis of G-CSF-supported chemotherapy regimens.

Tesch H, Indorf M, Chang D, Ottilinger B. Onkologie. 2012;35 (Suppl 6)(P236):72.

Filgrastim-NIS 2012 DGHO
Umsetzung von Leitlinien in der klinischen Praxis. Was können wir aus Klinischen Tumorregistern lernen?

Marschner N, Kopfmann S. FORUM. 2012;27(6):465–8.

Tumorregister 2012 FORUM
Register in der onkologischen Versorgungsforschung.

Klinkhammer-Schalke M, Marschner N, Hofstädter F. Der Onkologe. 2012 Jan 27;18(2):142–50.

Tumorregister 2012 Der Onkologe
Treatment of cancer- and chemotherapy-associated anemia with ferric carboxymaltose in clinical practice.

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, u. a. Onkologie. 2011;34 (Suppl.6)(V1012):304.

Ferinject-NIS 2011 DGHO
Analysis of the non-interventional study with Filgrastim-Hexal®: safety profile and patient perception.

Tesch H, Indorf M, Schmid T, Rauh J, Stoetzer O, Schaller-Kranz T. Onkologie. 2011;34 (Suppl.6)(P867):259.

Filgrastim-NIS 2011 DGHO
Ferric Carboxymaltose for the Correction of Cancer- and Chemotherapy-Assiciated Anemia in Clinical Practice.

Steinmetz T, Tschechne B, Virgin G, Klement B, Franzem M, Wamhoff J, u. a. haematologica. 2011;96(s2):0983.

Ferinject-NIS 2011 EHA
Intention of Treating Chemotherapy-Induced Neutropenia with Biosimilar Filgrastim and Change of Practice.

Tesch H, Turner M, Indorf M. 2011;

Filgrastim-NIS 2011 SIOG
Supportive Treatment of Chemotherapy-Induced Neutropenia with Biosimilar Filgrastim: the HEXAFIL Non-Interventional Study.

Tesch H, Indorf M, Schaller-Kranz T. EMCC / ESMO. 2011;(Poster 280, Abstract 4025):308.

Filgrastim-NIS 2011 EMCC (ESMO)
Effectiveness and tolerability of ferric carboymaltose in the correction of cancer- and chemotherapy-associated anaemia – a multicenter observational study.

Steinmetz T, Tschechne B, Virgin G, Klement B, Rzychon B, Franzem M, u. a. EMCC / ESMO. 2011;(Poster 294, Abstract 3000).

Ferinject-NIS 2011 EMCC (ESMO)
Treatment of tumor induced iron deficiency with ferric carboxymaltose (FCM, ferinject®).

Steinmetz T, Tschechne B, Selak E, Kellner T, Schröder D, Marschner N, u. a. Onkologie. 2010;33 (suppl 6)(Poster P250):74.

Ferinject-NIS 2010 DGHO
HEXAFIL: Non-interventional study for supportive treatment of chemotherapy induced neutopenia with Filgrastim HEXAL®.

Tesch H, Indorf M, Hartmann U. Onkologie. 2010;33(suppl 6)(P241):71.

Filgrastim-NIS 2010 DGHO
Klinische Tumorregister als Instrument der Versorgungsforschung: Das Netzwerk der niedergelassenen Hämatologen und Onkologen.

Marschner N, Jänicke M. Remission. 2010;3;3-5.

Tumorregister 2010 Remission
Krebsregister in der ambulanten Versorgung.

Marschner N. Aufwand und Nutzen. FORUM. 2009;24(1):35–7.

Tumorregister 2009 FORUM
Ambulatory care in Germany: Randomized controlled trials meet clinical practice.

Marschner N. Onkologie. 2009;32 (suppl 4):3.

Tumorregister 2009 DGHO
Epidemiological register of the image of antiemetic-strategies in the everyday routine.

Schröder J, Boeckmann W, Wiegand J, Eggert J, Jehner P, Dörfel S, u. a. Onkologie. 2009;32 (suppl 4):143.

Emesis-Register 2009 DGHO

Merken

iOMEDICO AG
Hanferstraße 28
D-79108 Freiburg

Phone: 0761 - 15 242 0
E-Mail: info@iomedico.com